Exploring lipoprotein(a) and incident heart failure in cancer patients with anthracycline-associated neoplasms
Anthracyclines remain cornerstone therapy for ~2.7 million cancer patients annually, conferring up to 30% survival benefits. However, dose-dependent cardiotoxicity affects ~9% of patients, manifesting as heart failure (HF). Lipoprotein(a) [Lp(a)], a genetically determined biomarker, promotes oxidative stress and...